跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CANHERA® LYOPHILIZED POWDER FOR INJECTION 440MG PER VIAL - HSA Drug Approval Details
Approvals
/
HSA
/
CANHERA® LYOPHILIZED POWDER FOR INJECTION 440MG PER VIAL
Approved
THERAPEUTIC
CANHERA® LYOPHILIZED POWDER FOR INJECTION 440MG PER VIAL
Biocon Biologics India Limited (Powder & Solvent)
🇸🇬 Health Sciences Authority
Approval Date
Nov 25, 2021
Approval ID
3e842a156fec895a
Company
Biocon Biologics India Limited (Powder & Solvent)
Type
Therapeutic
Approval Details
Approval Id
3e842a156fec895a
Drug Name
CANHERA® LYOPHILIZED POWDER FOR INJECTION 440MG PER VIAL
Product Name
CANHERA® LYOPHILIZED POWDER FOR INJECTION 440MG PER VIAL
Approval Number
SIN16384P
Approval Date
2021-11-25
Registrant
PHARMA TO MARKET PTE. LTD.
Drug Type
Therapeutic
Forensic Classification
Prescription Only
Dosage Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route Of Administration
INTRAVENOUS
Atc Code
L01XC03
Atc Item Name
xl 01 xc 03
Pharma Manufacturer Name
PHARMA TO MARKET PTE. LTD.
Company Detail Path
/organization/pharma-to-market-pte-ltd
Active Ingredients
Trastuzumab
440 mg/vial
Trastuzumab
440 mg/vial
Approved
Quick Info
Agency
HSA
Country
🇸🇬
Approval Date
Nov 25, 2021
Approval ID
3e842a156fec895a
Type
Therapeutic
Back to HSA Approvals
